期刊文献+

乙型肝炎人免疫球蛋白抗-HBs效价酶联免疫方法的建立 被引量:1

Establishment of the ELISA Method for Determination of Anti-HBs Potency of Human Hepatitis B Immunoglobulin
下载PDF
导出
摘要 目的:建立酶联免疫法检测乙型肝炎人免疫球蛋白抗-HBs效价的测定方法。方法:依据2015年版中国药典的规定,乙型肝炎人免疫球蛋白抗-HBs效价采用酶联免疫法测定,并应用生物检定统计法中的量反应平行线法设计实验,检测实验可靠性,计算效价。结果:每次实验的可靠性均符合2015年版中国药典规定,可信限率在10%以内,专属性强,试剂盒和仪器因素检测结果经F检验,差异无统计学意义(P>0.05),重复性RSD为1.61%。当抗-HBs效价在0.0512~0.1 IU·mL^(-1)范围内时,标准品和样品线性相关系数均大于0.99。7批样品与厂家放射免疫法的结果经F检验,无统计学差异(P>0.05)。结论:乙型肝炎人免疫球蛋白抗-HBs效价采用酶联免疫法测定,量反应平行线法分析,测定结果稳定、可靠,操作安全、快速、无污染,可用于乙型肝炎人免疫球蛋白抗-HBs效价检测。 Objective :To Establish the ELISA method to test the potency of anti –HBs on human hepatitis B immunoglobulin. Methods: According to the regulations of ChP. 2015,the ELISA was used for detecting the potency of anti –HBs on human hepatitis B immunoglobulin. Meanwhile, the quantity response parallel line analysis of bioassay-statistical was applied to design the experiment. The reliability was examined and the potency was calculated. Results: The reliable test of each experiment met the specification of ChP. 2015. The fiducial limit rate was within 10%. The specificity was good. The determination results by two different kits and instruments were analyzed by F test and showed no significant difference(P〉0.05). The relative standard substance deviation (RSD) in reproducibility test was 1.61 %. While the anti –HBs potency of standard and samples were between 0.0512 IU.mL-1~0.1 IU.mL-1, the linear correlation coefficients (r values) were both more than 0.99.The result of 7 batches of samples showed no statistical difference (P〉0.05) by F test with manufacturers radioimmunoassay. Conclusion: The testing results were stable and reliable. The operation was safe, rapid and without contamination. The anti –HBs potency on human hepatitis B immunoglobulin detected by the ELISA method and analyzed by the quantity response parallel line was validated.
出处 《中国药品标准》 CAS 2017年第6期439-442,共4页 Drug Standards of China
关键词 量反应平行线法 酶联免疫法 抗-HBs效价 乙型肝炎人免疫球蛋白 quantity response parallel line analysis ELISA anti-HBs potency human hepatitis B immunoglobulin
  • 相关文献

参考文献4

二级参考文献24

  • 1王开正,郑任之,苑冀蓉.ELISA法检测乙肝标志物室内质控病人标本结果分析[J].陕西医学检验,1993,8(1):46-47. 被引量:1
  • 2张弋,窦志高.ELISA法与MEIA法快速定量检测肝移植患者乙肝免疫球蛋白滴度[J].中国药师,2005,8(5):404-405. 被引量:1
  • 3林学辉.抗生素生物检定可信限率的控制方法探讨.中国药事,2000,14(3):207-207.
  • 4FDA/CDER/CVM.Guidance for Industry:Bioanalytical Method Validation[EB/OL].2001[2013-07-28].http://wenku.baidu.com/view/f36635d1240c844769eaee00.html.
  • 5EMEA.Guideline on Validation of Bioanalytical Methods(EMEA/CHMP/EWP/192217/2009)[EB/OL].2012[2013-07-28].http://wenku.baidu.com/view/6f5bfa0852ea551810a68749.html.
  • 6International Standard Organization.Statistics-Vocabulary and symbols-Part 2:Applied statistics (ISO 3534-2)[S].Second edition.2006-09-15.
  • 7Harmonised Tripartite Guideline(ICH).Validation of Analytical Procedures:Text and Methodology (ICH Q2(R1))[EB/OL].2005[2013-07-28].http://www.ich.org.
  • 8EURACHEM.Guide:The Fitness for Purpose of Analytical Methods;A Laboratory Guide to Method Validation and Related Topics[EB/OL].1998[2013-07-28].http://www.eurachem.org.
  • 9Solomon PJ.Variance Components,in Encyclopedia of Biostatistics[M].Chichester:John Wiley & Sons Ltd.,2005.5685.
  • 10SAS Institute Inc.SAS/STAT 12.3 User's Guide[M].Cary,NC:SAS Institute Inc.,2013.8531.

共引文献13

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部